SEARCH

SEARCH BY CITATION

10.8 References

  • 1
    Health Protection Agency. Malaria imported into the United Kingdom in 2005: implications for those advising travellers. Commun Dis Rep CDR Wkly 2006; 16: 23.
  • 2
    Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethn Health 2005; 10: 355372.
  • 3
    Cohen C, Karstaedt A, Frean J et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin Infect Dis 2005; 41: 16311637.
  • 4
    Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004; 18: 547554.
  • 5
    Whitworth J, Morgan D, Quigley M et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 10511056.
  • 6
    Lalloo DG, Shingadia D, Pasvol G et al. UK malaria treatment guidelines. J Infect 2007; 54: 111121.
  • 7
    ter Kuile FO, Parise ME, Verhoeff FH et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004; 71 (2 Suppl): 4154.
  • 8
    Jelinek T. Malaria self-testing by travellers: opportunities and limitations. Travel Med Infect Dis 2004; 2: 143148.
  • 9
    Makler MT, Piper RC, Milhous WK. Lactate dehydrogenase and the diagnosis of malaria. Parasitol Today 1998; 14: 376377.
  • 10
    Humar A, Ohrt C, Harrington MA, Pillai D, Kain KC. Parasight F test compared with the polymerase chain reaction and microscopy for the diagnosis of Plasmodium falciparum malaria in travellers. Am J Trop Med Hyg 1997; 56: 4448.
  • 11
    UK Health Departments. Management and Control of Viral Haemorrhagic Fevers: Summary of Guidance from the Advisory Committee on Dangerous Pathogens 1996. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947341973 (last accessed 28 September 2009).
  • 12
    WHO guidelines for malaria treatment: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (accessed 13 April 2011)
  • 13
    Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005; 19: 9951005.
  • 14
    Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol 2010; 69: 262270.
  • 15
    Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009; 61: 439443.
  • 16
    Newton PN, Ward S, Angus BJ et al. Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Trans R Soc Trop Med Hyg 2006; 100: 184186.
  • 17
    Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297: 22102219.
  • 18
    Gasasira AF, Kamya MR, Achan J et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46: 985991.
  • 19
    German P, Greenhouse B, Coates C et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007; 44: 889891.
  • 20
    Kredo T, van der Walt JS, Mauff K, Weisner L, Maartens G, Cohen K, Smith P, Barnes KI. Nevirapine increases lumefantrine exposure in HIV-infected patients. 17th Conference on Opportunistic Infections and Retroviruses. February 2010. San Francisco, Ca. Abstract N-140.
  • 21
    German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424429.
  • 22
    Health Protection Agency. Malaria. http://www.hpa.org.uk/infections/topics_az/malaria/default.htm (last accessed January 2011).
  • 23
    National Travel Health Network and Centre (NaTHNaC). Protecting the health of British travellers. http://www.nathnac.org (last accessed 28 September 2009).
  • 24
    Health Protection Scotland. Travel Health. http://www.hps.scot.nhs.uk/travel/fitfortravel.aspx (last accessed 28 September 2009).
  • 25
    Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med 2000; 7: 59.
  • 26
    van Riemsdijk MM, Sturkenboom MC, Ditters JM et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 2004; 57: 506512.
  • 27
    van Luin M, Van der Ende ME, Richter C et al. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS 2010; 24: 12231226.
  • 28
    World Health Organization. Leishmaniasis. http://www.who.int/leishmaniasis/leishmaniasis_maps/en/index.html (last accessed 28 September 2009).
  • 29
    Russo R, Laguna F, Lopez-Velez R et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 2003; 97 (Suppl. 1): 99105.
  • 30
    Altes J, Salas A, Riera M et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS 1991; 5: 201207.
  • 31
    Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97 (Suppl. 1): 315.
  • 32
    Alvar J, Canavate C, Gutierrez-Solar B et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10: 298319.
  • 33
    Piscopo TV, Mallia AC. Leishmaniasis. Postgrad Med J 2006; 82: 649657.
  • 34
    Riera C. Observations on ‘seroepidemiology study of Leishmania infantum infection in Castilla-Leon, Spain’. Am J Trop Med Hyg 2005; 73: 231.
  • 35
    Russo R, Nigro LC, Minniti S et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32: 133137.
  • 36
    Laguna F, Videla S, Jimenez-Mejias ME et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003; 52: 464468.
  • 37
    Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43: 917924.
  • 38
    Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bonza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80: 5473.
  • 39
    Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97 (Suppl. 1): 135142.
  • 40
    Perez-Molina JA, Lopez-Velez R, Montilla P, Guerrero A. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS 1996; 10: 237238.
  • 41
    López-Vélez R, Videla SSpanish HIV-Leishmania Study Group et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53: 540543.
  • 42
    Molina I, Falco V, Crespo M et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007; 60: 837842.
  • 43
    Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39: 15201523.
  • 44
    Marques N, Sá R, Coelho F, Oliveira J, Saraiva Da Cunha J, Meliço-Silvestre A. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scand J Infect Dis 2008; 40: 523526.
  • 45
    Troya J, Casquero A, Refoyo E, Fernández-Guerrero ML, Górgolas M. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 2008; 40: 7880.
  • 46
    Collini P, Premchand N, Lockwood D, Greig J. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature. Ann Trop Med Parasitol 2009; 103: 455459.
  • 47
    Barragán P, López-Velez R, Olmo M, Podzamczer D. Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2010; 83: 1012.
  • 48
    Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53: 158166.
  • 49
    Mira JA, Corzo JE, Rivero A et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70: 298301.
  • 50
    Casado JL, Lopez-Velez R, Pintado V, Querada C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20: 202205.
  • 51
    Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in two patients with AIDS. J Infect Dis 2005; 192: 18191822.
  • 52
    Antinori S, Longhi E, Bestetti G et al. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 2007; 157: 10321036.
  • 53
    Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20: 482488.
  • 54
    Vaidian AK, Weiss LM, Tanowitz HB. Chagas' disease and AIDS. Kinetoplastid Biol Dis 2004; 3: 2.
  • 55
    Ferreira MS, Nishioka Sde A, Silvestre MT, Borges AS, Nunes-Araújo FR, Rocha A. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 1997; 25: 13971400.
  • 56
    Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9: 324330.
  • 57
    Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis 2007; 45: 12081213.
  • 58
    Pagano MA, Segura MJ, Di Lorenzo GA et al. Cerebral tumor-like American trypanosomiasis in acquired immunodeficiency syndrome. Ann Neurol 1999; 45: 403406.
  • 59
    Burgos JM, Begher SB, Freitas JM et al. Molecular diagnosis and typing of Trypanosoma cruzi populations and lineages in cerebral Chagas disease in a patient with AIDS. Am J Trop Med Hyg 2005; 73: 10161018.
  • 60
    Cordova E, Boschi A, Ambrosioni J, Cudos C, Corti M. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992–2007. Int J Infect Dis 2008; 12: 587592.
  • 61
    Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58 (RR-4): 1207. Available at: http://aidsinfo.nih.gov/contentfiles/Adult_OI.pdf (last accessed January 2011).
  • 62
    Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther 2010; 4: 243253.
  • 63
    Ferreira MS, Borges AS. Some aspects of protozoan infections in immunocompromised patients- a review. Mem Inst Oswaldo Cruz 2002; 97: 443457.
  • 64
    Hajjeh RA, Pappas PG, Henderson H et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 2001; 32: 12151220.
  • 65
    Manfredi R, Mazzoni A, Nanetti A, Chiodo F. Histoplasmosis capsulati and duboisii in Europe: the impact of the HIV pandemic, travel and immigration. Eur J Epidemiol 1994; 10: 675681.
  • 66
    Pappas PG, Pottage JC, Powderly WG et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116: 847853.
  • 67
    Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005; 41: 11741178.
  • 68
    McKinsey DS, Spiegel RA, Hutwagner L et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 1997; 24: 11951203.
  • 69
    Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 688695.
  • 70
    Wheat LJ, Connolly-Stringfield PA, Baker RL et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69: 361374.
  • 71
    Singh VR, Smith DK, Lawrence J et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996; 23: 563568.
  • 72
    Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 22: 671682.
  • 73
    Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996; 22 (Suppl. 2): S102S111.
  • 74
    Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis 2010; 50: 17.
  • 75
    Wheat LJ, Connolly-Stringfield P, Williams B et al. Diagnosis of histoplasmosis in patients with the acquired immunodeficiency syndrome by detection of Histoplasma capsulatum polysaccharide antigen in bronchoalveolar lavage fluid. Am Rev Respir Dis 1992; 145: 14211424.
  • 76
    Corcoran GR, Al-Abdely H, Flanders CD, Geimer J, Patterson TF. Markedly elevated serum lactate dehydrogenase levels are a clue to the diagnosis of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis 1997; 24: 942944.
  • 77
    Buitrago MJ, Berenguer J, Mellado E, Rodriguez-Tudela, Cuenca-Estrella M. Detection of imported histoplasmosis in serum of HIV-infected patients using a real-time PCR-based assay. Eur J Clin Microbiol Infect Dis 2006; 25: 665668.
  • 78
    Chapman SW, Bradsher RW Jr, Campbell GD Jr, Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 679683.
  • 79
    Wheat J, Hafner R, Korzun AH et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995; 98: 336342.
  • 80
    Fish DG, Ampel NM, Galgiani JN et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69: 384391.
  • 81
    Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137: 105109.
  • 82
    Galgiani JN, Ampel NM, Catanzaro C, Johnson RH, Stevens DA, Williams PL. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 658661.
  • 83
    Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007; 55: 287299.
  • 84
    Restrepo A, Tobon A, Clark B et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54: 319327.
  • 85
    Kataria YP, Campbell PB, Burlingham BT. Acute pulmonary histoplasmosis presenting as adult respiratory distress syndrome: effect of therapy on clinical and laboratory features. South Med J 1981; 74: 534537, 542.
  • 86
    Goldman M, Zackin R, Fichtenbaum CJ et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38: 14851489.
  • 87
    Shelburne SA, Visnegarwala F, Adams C, Krause KL, Hamill RJ, White AC. Unusual manifestations of disseminated histoplasmosis in patients responding to antiretroviral therapy. Am J Med 2005; 118: 10381041.
  • 88
    Nacher M, Sarazin F, El Guedj M et al. Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. J Acquir Immune Defic Syndr 2006; 41: 468470.
  • 89
    Breton G, Adle-Biassette H, Therby A et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20: 119121.
  • 90
    Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23: 125130.
  • 91
    Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344: 110113.
  • 92
    Sobottka I, Albrecht H, Mack D et al. Systemic Penicillium marneffei infection in a German AIDS patient. Eur J Clin Microbiol Infect Dis 1996; 15: 256259.
  • 93
    Rimek D, Zimmermann T, Hartmann M, Prariyachatiqul C, Kappe R. Disseminated Penicillium marneffei infection in an HIV-positive female from Thailand in Germany. Mycoses 1999; 42 (Suppl. 2): 2528.
  • 94
    Remadi S, Lotfi C, Finci V et al. Penicillium marneffei infection in patients infected with the human immunodeficiency virus. A report of two cases. Acta Cytol 1995; 39: 798802.
  • 95
    Filiotou A, Velegraki A, Giannaris M et al. First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole. Am J Med Sci 2006; 332: 4345.
  • 96
    Antinori S, Gianelli E, Bonaccorso C et al. Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. J Travel Med 2006; 13: 181188.
  • 97
    Skoulidis F, Morgan MS, MacLeod KM. Penicillium marneffei: a pathogen on our doorstep? J R Soc Med 2004; 97: 394396.
  • 98
    Peto TE, Bull R, Millard PR et al. Systemic mycosis due to Penicillium marneffei in a patient with antibody to human immunodeficiency virus. J Infect 1988; 16: 285290.
  • 99
    Ranjana KH, Priyokumar K, Singh TJ et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002; 45: 268271.
  • 100
    Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994–1998: regional variation and temporal trends. Clin Infect Dis 2001; 32: 955962.
  • 101
    Sun HY, Chen MY, Hsiao CF, Hsieh SM, Hung CC, Chang SC. Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active antiretroviral therapy. Clin Microbiol Infect 2006; 12: 381388.
  • 102
    McShane H, Tang CM, Conlon CP. Disseminated Penicillium marneffei infection presenting as a right upper lobe mass in an HIV positive patient. Thorax 1998; 53: 905906.
  • 103
    Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin Infect Dis 2002; 35: 10881095.
  • 104
    Desakorn V, Smith MD, Walsh AL et al. Diagnosis of Penicillium marneffei infection by quantitation of urinary antigen by using an enzyme immunoassay. J Clin Microbiol 1999; 37: 117121.
  • 105
    Imwidthaya P, Thipsuvan K, Chaiprasert A, Danchaivijitra S, Sutthent R, Jearanaisilavong J. Penicillium marneffei: types and drug susceptibility. Mycopathologia 2001; 149: 109115.
  • 106
    Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26: 11071110.
  • 107
    Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339: 17391743.
  • 108
    Hung CC, Chen MY, Hsieh SM, Sheng WH, Hsiao CF, Chang SC. Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy. AIDS 2002; 16: 672673.
  • 109
    Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS 2007; 21: 365367.
  • 110
    Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700705.
  • 111
    Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34: 277284.
  • 112
    Perlman DC, Carey J. Prevention of disseminated Penicillium marneffei in human immunodeficiency virus-infected travelers. J Travel Med 2006; 13: 386; author reply 387.
  • 113
    Manosuthi W, Chaovavanich A, Tansuphaswadikul S et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect 2007; 55: 464469.